TRCT
PARN

Tower Research Capital (TRC)’s Parnell Pharmaceuticals Holdings Ltd PARN Stock Holding History

Tower Research Capital (TRC)’s Portfolio PARN Stock Details PARN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-690
Closed -$1K – 5079
2016
Q3 		$1K Hold
690
– – ﹤0.01% 3530
2016
Q2 		$1K Sell
690
-357
-34% -$656 ﹤0.01% 4366
2016
Q1 		$2K Buy
1,047
+747
+249% +$2.06K ﹤0.01% 3607
2015
Q4 		$1K Buy
+300
New +$1.14K ﹤0.01% 4375
2015
Q3 		– Sell
-131
Closed -$1K – 5686
2015
Q2 		$1K Sell
131
-2,010
-94% -$8.87K ﹤0.01% 4279
2015
Q1 		$11K Buy
2,141
+1,324
+162% +$6.12K ﹤0.01% 2764
2014
Q4 		$3K Sell
817
-714
-47% -$3.24K ﹤0.01% 3286
2014
Q3 		$9K Buy
+1,531
New +$9.22K ﹤0.01% 2956

Other funds holding PARN

BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Tower Research Capital (TRC)'s PARN Position: Q4 2016 in Review

Tower Research Capital (TRC) sold out of Parnell Pharmaceuticals Holdings Ltd (PARN) in Q4 2016, closing a stake of 690 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in PARN in Q3 2014 and held it in 8 quarters. The position peaked at $11K in Q1 2015. 20 funds tracked by Wall St. Rank hold PARN as of Q4 2016.

  • Tower Research Capital (TRC) reported no remaining Parnell Pharmaceuticals Holdings Ltd position as of Q4 2016 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 690 Parnell Pharmaceuticals Holdings Ltd shares in Q4 2016, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Parnell Pharmaceuticals Holdings Ltd in Q3 2014 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s Parnell Pharmaceuticals Holdings Ltd position peaked at $11K in Q1 2015.
  • 20 funds tracked by Wall St. Rank held Parnell Pharmaceuticals Holdings Ltd as of Q4 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2016, filed 3 Feb 2017.